Literature DB >> 11374876

C-peptide binding to human cell membranes: importance of Glu27.

A Pramanik1, K Ekberg, Z Zhong, J Shafqat, M Henriksson, O Jansson, A Tibell, M Tally, J Wahren, H Jörnvall, R Rigler, J Johansson.   

Abstract

In addition to its established role in proinsulin folding, C-peptide has a function in regulation of cellular activity. The 31-residue peptide influences renal, vascular, and metabolic functions in patients with insulin-dependent diabetes mellitus. Binding to cells has been demonstrated for C-peptide, which can be displaced by its C-terminal pentapeptide. We have now used fluorescence correlation spectroscopy to investigate structural requirements on the pentapeptide part for C-peptide binding. All pentapeptide residues, E(27)GSLQ(31), were individually replaced with Ala and the capacity of the resulting peptides to displace rhodamine-labelled full-length human C-peptide from human renal tubular cell membranes was determined. This showed that Glu27 is essential for displacement, while replacement of Gly28 with Ala has little effect, and replacement of any of the three most C-terminal residues had intermediate effects. Morevover, free Glu displaces full-length C-peptide to about 50%, while free Ala, C-peptide(1-26), and the truncated pentapeptide, corresponding to the tetrapeptide G(28)SLG(31), have no displacing capacity. The peptides EVARQ (corresponding to the rat C-terminal pentapeptide) and ELGGGPGAG (corresponding to positions 11-19 of human C-peptide) do not displace human C-peptide. These results indicate that Glu27 of C-peptide is critically involved in binding to cellular targets. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374876     DOI: 10.1006/bbrc.2001.4917

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells.

Authors:  N M Al-Rasheed; F Meakin; E L Royal; A J Lewington; J Brown; G B Willars; N J Brunskill
Journal:  Diabetologia       Date:  2004-05-26       Impact factor: 10.122

2.  C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes.

Authors:  P Luppi; X Geng; V Cifarelli; P Drain; M Trucco
Journal:  Diabetologia       Date:  2009-08-07       Impact factor: 10.122

Review 3.  C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?

Authors:  C W Pinger; K E Entwistle; T M Bell; Y Liu; D M Spence
Journal:  Mol Biosyst       Date:  2017-07-25

Review 4.  Insights into the physiology of C-peptide.

Authors:  D Vejrazkova; M Vankova; P Lukasova; J Vcelak; B Bendlova
Journal:  Physiol Res       Date:  2020-09-30       Impact factor: 1.881

Review 5.  Physiological effects and therapeutic potential of proinsulin C-peptide.

Authors:  Gina L C Yosten; Christine Maric-Bilkan; Patrizia Luppi; John Wahren
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-09-23       Impact factor: 4.310

6.  Anti-inflammatory properties of C-Peptide.

Authors:  Jaime Haidet; Vincenza Cifarelli; Massimo Trucco; Patrizia Luppi
Journal:  Rev Diabet Stud       Date:  2009-11-10

7.  C-Peptide versus insulin: relationships with risk biomarkers of cardiovascular disease in metabolic syndrome in young arab females.

Authors:  A Abdullah; H Hasan; V Raigangar; W Bani-Issa
Journal:  Int J Endocrinol       Date:  2012-08-01       Impact factor: 3.257

8.  pH-Dependent Interaction between C-Peptide and Phospholipid Bicelles.

Authors:  Sofia Unnerståle; Lena Mäler
Journal:  J Biophys       Date:  2012-07-16

Review 9.  Pharmacology under the microscope: the use of fluorescence correlation spectroscopy to determine the properties of ligand-receptor complexes.

Authors:  Stephen J Briddon; Stephen J Hill
Journal:  Trends Pharmacol Sci       Date:  2007-11-14       Impact factor: 14.819

10.  C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients.

Authors:  Thomas Hach; Thomas Forst; Thomas Kunt; Karin Ekberg; Andreas Pfützner; John Wahren
Journal:  Exp Diabetes Res       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.